Recently released papers with findings from two National Institutes of Health-funded studies by the Center for Solutions for ME/CFS & The Jackson Laboratory indicate that microbiome changes may be a signature for ME/CFS.
The NIH reports, “Findings from two studies, published in Cell Host & Microbe and funded by the National Institutes of Health add to growing evidence that connects disruptions in the gut microbiome, the complete collection of bacteria, viruses, and fungi that live in our gastrointestinal system, to ME/CFS.”
Vicky Whittemore, Ph.D., program director at NIH’s National Institute of Neurological Disorders and Stroke (NINDS), noted, “The microbiome has emerged as a potential contributor to ME/CFS. These findings provide unique insights into the role the microbiome plays in the disease and suggest that certain differences in gut microbes could serve as biomarkers for ME/CFS.”
Solve CEO Oved Amitay notes that the studies represent important first steps toward the development of clinical diagnostic tests, and further investment will help bring these scientific breakthroughs over the finish line. Read his comments on how Solve is getting stakeholders involved to address this unmet need.
For more information on the two microbiome studies, read the NIH press release here and the NIH Director’s Blog on the studies here.
Read the full articles here:
Guo, et al. Deficient butyrate-producing capacity in the gut microbiome is associated with bacterial network disturbances and fatigue symptoms in ME/CFS. Cell Host & Microbe, February 8, 2023. DOI: 10.1016/j.chom.2023.01.004
Xiong, et al. Multi-‘omics of host-microbiome interactions in short- and long-term Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Cell Host & Microbe, February 8, 2023.
DOI: 10.1016/j.chom.2023.01.001
A third significant ME/CFS study was recently published. Read it here:
Nepotchatykh, E., Caraus, I., Elremaly, W. et al. Circulating microRNA expression signatures accurately discriminate myalgic encephalomyelitis from fibromyalgia and comorbid conditions. Sci Rep 13, 1896 (2023). https://doi.org/10.1038/s41598-023-28955-9
